Centuple Global Ltd
Incorporated in 1991, Checkpoint Trends Ltd is in the business of trading and consultancy[1]
- Market Cap ₹ 24.2 Cr.
- Current Price ₹ 44.3
- High / Low ₹ 144 / 16.1
- Stock P/E 16.1
- Book Value ₹ 42.5
- Dividend Yield 0.00 %
- ROCE 15.0 %
- ROE 12.7 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 1.04 times its book value
- Company's median sales growth is 26.2% of last 10 years
- Company's working capital requirements have reduced from 182 days to 14.7 days
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 12.3% over last 3 years.
- Company might be capitalizing the interest cost
- Company has high debtors of 215 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 0 | 0 | 2 | 1 | 1 | 0 | 2 | 1 | 1 | 0 | 574 | |
| 0 | 0 | 0 | 2 | 1 | 1 | 0 | 2 | 1 | 1 | 0 | 572 | |
| Operating Profit | -0 | -0 | 0 | -0 | -0 | 0 | 0 | -0 | -0 | 0 | 0 | 2 |
| OPM % | -5% | 10% | -1% | -31% | 2% | 2% | -1% | -7% | 3% | 20% | 0% | |
| -3 | 0 | 0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | 0 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | -3 | -0 | 0 | -0 | -0 | 0 | 0 | -0 | -0 | 0 | 0 | 2 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 20% | 0% | 50% | 0% | -50% | 40% | 34% |
| -3 | -0 | 0 | -0 | -0 | 0 | 0 | -0 | -0 | 0 | 0 | 2 | |
| EPS in Rs | -5.61 | -0.02 | 0.05 | -0.29 | -0.02 | 0.05 | 0.02 | -0.07 | -0.15 | 0.05 | 0.05 | 2.76 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 122% |
| 5 Years: | 311% |
| 3 Years: | 691% |
| TTM: | 114662% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 65% |
| 5 Years: | 173% |
| 3 Years: | 175% |
| TTM: | 2920% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 64% |
| 3 Years: | 108% |
| 1 Year: | 149% |
| Return on Equity | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 10% |
| 3 Years: | 12% |
| Last Year: | 13% |
Balance Sheet
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Reserves | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -5 | -5 | 18 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 313 | |
| Total Liabilities | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 343 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 343 | |
| Total Assets | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 343 |
Cash Flows
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0 | -0 | 0 | 0 | -0 | 0 | 1 | -0 | 0 | 0 | 0 | ||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | -0 | ||
| -0 | -0 | 0 | 0 | -0 | -0 | 0 | 0 | 0 | 0 | 0 | ||
| Net Cash Flow | -0 | -0 | 0 | 0 | -0 | -0 | 1 | -0 | 0 | -0 | 0 | |
| Free Cash Flow | -0 | -0 | 0 | 0 | -0 | 0 | 1 | -0 | 0 | -0 | 0 | |
| CFO/OP | 114% | 100% | 133% | -600% | 17% | 650% | 5,200% | 2,450% | -12% | 0% | 190% |
Ratios
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 36 | 24 | 54 | 179 | 107 | 164 | 122 | 135 | 229 | 212 | 215 | |
| Inventory Days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | ||||
| Days Payable | 197 | |||||||||||
| Cash Conversion Cycle | 36 | 24 | 54 | 179 | 107 | 164 | 122 | 135 | 229 | 212 | 19 | |
| Working Capital Days | 18 | -35 | 36 | 260 | 221 | 60 | 98 | 129 | 145 | 387 | 15 | |
| ROCE % | -3% | -3% | 7% | 25% | -31% | 3% | 2% | -3% | -13% | 3% | 17% | 15% |
Insights
In beta| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Electricity Consumption Cost INR |
|
|||||||||||
| Debtors Turnover Ratio Ratio |
||||||||||||
| Number of Shareholders Count |
||||||||||||
| Percentage of Shares in Dematerialized Form % |
||||||||||||
| Number of Permanent Employees Count |
||||||||||||
Extracted by Screener AI
Documents
Announcements
- Announcement under Regulation 30 (LODR)-Newspaper Publication 13h
-
Audited Financial Result For The Quarter And Year Ended March 31, 2026
30 May - Board approved FY26 audited standalone results; auditors gave unmodified opinion; UK subsidiary still pending; borrowings at ₹6.73 crore.
-
Board Meeting Outcome for Outcome Of Board Meeting
30 May - Board approved FY26 audited standalone results; auditors issued unmodified opinion; trading window opens June 2, 2026.
-
Announcement under Regulation 30 (LODR)-Resignation of Director
26 May - Kumar Anubhav Upadhyay resigned as Whole-time Director effective May 26, 2026.
- Announcement under Regulation 30 (LODR)-Newspaper Publication 26 May
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
CTL (Formerly Rubra Medicaments Ltd) was engaged in the manufacture and sale of pharmaceutical formulations based in Hyderabad. The company is currently in the business of trading and providing different kinds of consulting services in India to all categories of clients.